New radioactive drug targets Hard-to-Treat prostate cancer
NCT ID NCT07414940
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests a new injectable radioactive drug, Actinium-225 rhPSMA-10.1, in 60 men with advanced prostate cancer that has spread and stopped responding to other treatments. The drug is designed to attach to prostate cancer cells and destroy them with radiation. The study aims to find safe doses and see if the drug can shrink tumors or lower PSA levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Actinium-225 rhPSMA-10.1 (a radioactive drug injected into the body to target and destroy prostate cancer cells)
What this could lead to
If it works, this could offer a new treatment option for men with advanced prostate cancer who have run out of effective therapies.
What could go wrong
This is an early-phase trial with only 60 participants, so the drug may not prove safe or effective. Radioactive drugs can cause side effects like damage to healthy tissues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University College London Hospital
RECRUITINGLondon, WC1E 6BT, United Kingdom
Contact Email: •••••@•••••